| Document |
Document Title |
|
WO/2024/096721A1 |
The present invention relates to a composition for preventing, treating, or ameliorating a neurodegenerative disorder, comprising an Allium senescens extract as an active ingredient. The composition of the present invention reduces the l...
|
|
WO/2024/093907A1 |
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside a nucleotide, or at a 5' end and/or a 3' end, and is used for improving the ...
|
|
WO/2024/094217A1 |
The present application relates to a method of promoting pathological TDP-43 protein degradation, which comprises administering to a subject a therapeutically effective amount of one or more compounds among: a plasminogen activation path...
|
|
WO/2024/095905A1 |
The purpose of this invention is to provide a novel composition for suppressing amyloid β accumulation. The present invention relates to a composition for suppressing amyloid β accumulation, the composition containing cyclo(His-Pro) an...
|
|
WO/2024/094816A1 |
The invention provides a compound of formula (I), or a pharmaceutically acceptable salt, ester or carbamate thereof, or a salt of such an ester or carbamate, wherein either: R1 is OH, and R2 is H; or R1 is H, and R2 is OH. The invention ...
|
|
WO/2024/094235A1 |
Compounds based on benzoxaborole moiety with activity against parasitic amoeba of genus Naegleria can be used in treatment of diseases caused by such parasites. Activity of the compounds against Naegleria fowleri was proven by a phenotyp...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/089228A1 |
The present invention relates to substituted dioxane derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of neuronal and non-neuronal conditions having an ass...
|
|
WO/2024/092001A1 |
The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti...
|
|
WO/2024/090549A1 |
Provided is an agent for preventing or ameliorating neuropathy caused by decreased nerve function due to nerve damage or diabetic neuropathy. The agent for preventing or ameliorating neuropathy is obtained by combining one or more lact...
|
|
WO/2024/091299A1 |
Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1)...
|
|
WO/2024/091542A1 |
The present disclosure relates to compounds of formula (I), which are capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of said compounds and methods of using said compound...
|
|
WO/2024/088922A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
|
|
WO/2024/089632A1 |
Composition of extracellular vesicles and uses thereof for the treatment of neurological diseases comprising extracellular vesicles derived from stem cells selected from the group consisting of animal stem cells and cell lines. Said extr...
|
|
WO/2024/092070A1 |
Neuropsychiatric treatments, including methods, regimens, and interventions to treat anxiety and associated symptoms, based on ulotaront administration.
|
|
WO/2024/092205A1 |
The general field of the present disclosure are novel approaches to the treatment of Alzheimer's and other neurodegenerative disorders using novel therapeutics comprising SHIP1 phosphatase inhibitors. Specifically, the invention provides...
|
|
WO/2024/086933A1 |
Disclosed are novel fused mescaline derivative compounds, notably C1 -substituted isopropylamine fused heterocyclic mescaline derivatives, including C1-substituted isopropylamine fused dioxolane and fused dioxane mescaline derivatives (F...
|
|
WO/2024/088109A1 |
Provided are an aryl heterocyclic compound, a preparation method therefor, and a use thereof, and the structural formula of the aryl heterocyclic compound is as shown in formula (I). The provided compound has a monoaminergic system regul...
|
|
WO/2024/089247A1 |
The present invention relates to a compound for treatment of neuropathic pain. It also relates to pharmaceutical compositions thereof, as well as methods of treatment of neuropathic pain.
|
|
WO/2024/092238A1 |
Methods of improving cognitive function in a human subject, comprising parenterally administering to said subject at least one dose of a polypeptide, or a polynucleotide that is capable of expressing a polypeptide, that includes at least...
|
|
WO/2024/092069A1 |
The present invention provides CXCR4 inhibitors of Formula (I): and pharmaceutically acceptable salts thereof, and methods for their use in treating neurological and CNS diseases, disorders, and conditions.
|
|
WO/2024/092154A1 |
The present disclosure provides methods for achieving optimal levels of bevemipretide (also known as "(R)-2-amino-N-((S)- 1 -(((S)-5-amino- 1 -(3 -benzyl- 1,2,4-oxadiazol-5- yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropa
n-...
|
|
WO/2024/089465A2 |
The disclosure generally relates to methods of treatment to help a subject cess smoking, comprising at least one step during which the subject is administered an effective dose of an aqueous solution of an enriched protein tobacco leaf e...
|
|
WO/2024/088928A1 |
The invention relates to novel processes for manufacturing 6-[[5-methyl-3-(6-methyl-3- pyridyl)isoxazol-4-yl]methoxy]-N-tetrahydropyran-4-yl-pyrida
zine-3-carboxamide (1), or a pharmaceutically acceptable salt thereof. The processes acco...
|
|
WO/2024/091873A2 |
Disclosed herein are compositions comprising a small molecule that targets MTRES1. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a small molecule that targets MTRES1 ...
|
|
WO/2024/089296A1 |
The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of ...
|
|
WO/2024/088408A1 |
Disclosed are a nitrogen-containing heterocyclic compound, a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Provided is a compound as shown in formula (I) or a pharmaceutically acceptable sal...
|
|
WO/2024/092195A1 |
Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fuse...
|
|
WO/2024/088808A1 |
Provided are compositions containing microalgae extracellular vesicles (MEVs) formulated for intranasal delivery, whereby, upon intranasal administration the MEVs traffic through specific routes following intranasal administration to spe...
|
|
WO/2024/092251A1 |
Provided are methods for treating depression and depression-related conditions by combining administration of pharmacologic agents and neuromodulation induced by transcranial electrical stimulation.
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
|
WO/2024/087783A1 |
The present invention relates to compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, etc. are defined as in the description. Additionally, further provided are a preparation met...
|
|
WO/2024/088285A1 |
The present invention relates to a mesylate of a heterocyclic substituted fused γ-carboline derivative, a crystal form and a preparation method therefor and a use thereof. In particular, the present invention relates to a mesylate of co...
|
|
WO/2024/091523A1 |
The present disclosure relates in some aspects to certain phenethylamine analogs, such as benzocyclobutene and benzocyclopentene analogs, including those of Formula (1). Also provided are methods of synthesizing the compounds, compositio...
|
|
WO/2024/092083A1 |
Compositions and methods for inhibiting EPH-EPHRIN tetramerization are provided. The compounds and methods herein further comprise methods for administering novel EPH-EPHRIN tetramerization inhibitors to a subject in need thereof to trea...
|
|
WO/2024/091874A1 |
Disclosed herein are compositions comprising a MTRES1 gene therapy. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a MTRES1 gene therapy.
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
|
WO/2024/091556A1 |
Methods for identifying biomarkers indicative of an increased risk for developing hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunting (TIPS) are provided. Methods include determining whether the subject...
|
|
WO/2024/089667A1 |
The present invention relates to a pharmaceutical composition or formulation of arimoclomol citrate, either in monotherapy or in combination treatment therapy with miglustat, for use in one or more methods of treating Niemann Pick diseas...
|
|
WO/2024/091148A2 |
The invention relates to the chemical and pharmaceutical industry, and more particularly to a liquid balneological concentrate for preparing health-giving and therapeutic full or partial baths at health resorts and in other medical and w...
|
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
|
WO/2024/091538A1 |
The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
|
|
WO/2024/089226A1 |
The present disclosure relates to phenethylamine compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, polymorphs, or prodrugs thereof, to pharmaceutical compositions, and in some embodiments, to serotonin...
|
|
WO/2024/088712A1 |
The present invention relates to mGluR5 antagonists, or compounds 4-[5-[(rac)-1-[5-(3- Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol
-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, enantiomer, isotope...
|
|
WO/2024/088409A1 |
Disclosed in the present invention are nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof, a preparation method therefor, and the use thereof. Provided in the present invention are compounds represen...
|
|
WO/2024/089227A1 |
The present invention relates to compounds of formula I, a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an assoc...
|
|
WO/2024/089454A1 |
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of post viral infection caused by the virus strain called SARS-CoV-2, or alternatively COVID- 19, chronic fatigue/fa...
|
|
WO/2024/091079A1 |
The present application relates to a blood-brain barrier permeable fusion protein and a use thereof. The present application provides a pharmaceutical composition comprising a blood-brain barrier permeable fusion protein as an active ing...
|
|
WO/2024/090922A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cerebral nervous system diseases, comprising, as active ingredients, a stem cell culture and extracellular vesicles isolated therefrom. Particularly...
|
|
WO/2024/091541A1 |
The present disclosure relates to compounds of Formula (I) capable of modulating the activity of GPR52. The present disclosure further provides a process for the preparation of compounds of Formula (1) and methods of using compounds of F...
|
